AstraZeneca (LON:AZN)‘s stock had its “market perform” rating restated by Sanford C. Bernstein in a research note issued on Thursday, AR Network reports. They currently have a GBX 3,115 ($50.93) target price on the stock. Sanford C. Bernstein’s price target would indicate a potential downside of 9.63% from the company’s current price.
AstraZeneca (LON:AZN) opened at 3432.50 on Thursday. AstraZeneca has a one year low of GBX 2887.50 and a one year high of GBX 3544.50. The stock has a 50-day moving average of GBX 3352. and a 200-day moving average of GBX 3260.41. The company’s market cap is £43.009 billion.
A number of other firms have also recently commented on AZN. Analysts at Barclays reiterated an “equal weight” rating on shares of AstraZeneca in a research note to investors on Thursday. They now have a GBX 3,050 ($49.87) price target on the stock. Separately, analysts at JPMorgan Chase & Co. reiterated a “neutral” rating on shares of AstraZeneca in a research note to investors on Wednesday. Finally, analysts at Citigroup Inc. reiterated a “neutral” rating on shares of AstraZeneca in a research note to investors on Friday, December 6th. They now have a GBX 3,500 ($57.23) price target on the stock. Thirteen research analysts have rated the stock with a sell rating, fifteen have given a hold rating and four have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and a consensus price target of GBX 3,056.25 ($49.97).
AstraZeneca PLC (LON:AZN) is a global biopharmaceutical company.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.